Brookline Capital Management Predicts SCYNEXIS Q1 Earnings

SCYNEXIS, Inc. (NASDAQ:SCYX) – Equities research analysts at Brookline Capital Management issued their Q1 2025 earnings per share estimates for SCYNEXIS in a research report issued on Thursday, November 7th. Brookline Capital Management analyst K. Dolliver anticipates that the company will earn $0.00 per share for the quarter. The consensus estimate for SCYNEXIS’s current full-year earnings is ($0.68) per share. Brookline Capital Management also issued estimates for SCYNEXIS’s Q2 2025 earnings at $0.01 EPS, Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.05 EPS, FY2025 earnings at $0.05 EPS and FY2026 earnings at $0.88 EPS.

SCYNEXIS (NASDAQ:SCYX) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.14. The firm had revenue of $0.66 million for the quarter. SCYNEXIS had a negative return on equity of 66.21% and a negative net margin of 425.41%.

Separately, StockNews.com upgraded SCYNEXIS from a “sell” rating to a “hold” rating in a research report on Friday.

SCYNEXIS Price Performance

Shares of NASDAQ:SCYX opened at $1.31 on Monday. The company has a market cap of $49.71 million, a P/E ratio of -1.77 and a beta of 1.50. SCYNEXIS has a 1 year low of $1.26 and a 1 year high of $3.07. The stock’s fifty day moving average price is $1.45 and its 200-day moving average price is $1.81.

Insider Activity at SCYNEXIS

In other news, CEO Gonzalez David Angulo acquired 20,000 shares of SCYNEXIS stock in a transaction that occurred on Thursday, September 12th. The stock was bought at an average price of $1.37 per share, for a total transaction of $27,400.00. Following the completion of the transaction, the chief executive officer now owns 507,871 shares in the company, valued at $695,783.27. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.85% of the stock is owned by company insiders.

Institutional Trading of SCYNEXIS

A number of hedge funds and other institutional investors have recently bought and sold shares of SCYX. Empowered Funds LLC increased its position in SCYNEXIS by 8.1% in the first quarter. Empowered Funds LLC now owns 88,414 shares of the company’s stock worth $130,000 after buying an additional 6,650 shares in the last quarter. Vanguard Group Inc. increased its position in SCYNEXIS by 8.3% in the first quarter. Vanguard Group Inc. now owns 1,687,670 shares of the company’s stock worth $2,481,000 after buying an additional 129,153 shares in the last quarter. Finally, Acadian Asset Management LLC increased its position in SCYNEXIS by 5.4% in the first quarter. Acadian Asset Management LLC now owns 421,083 shares of the company’s stock worth $618,000 after buying an additional 21,700 shares in the last quarter. Hedge funds and other institutional investors own 54.37% of the company’s stock.

SCYNEXIS Company Profile

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.